GlassScriptPhysician profile
Yulian Khagi
NPI 1710253638
$83,595.86
in general payments reported to CMS, 2019-2025
20 companies · $76.62 in 2025
The $76.62 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $7,565 · 2021: $14K · 2022: $22K · 2023: $10K · 2024: $4,469 · 2025: $76.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,479 · Consulting Fee: $3,360 · Travel and Lodging: $1,041 · Food and Beverage: $737 · Education: $88.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,478.50 |
| Consulting Fee | $3,360.00 |
| Travel and Lodging | $1,041.13 |
| Food and Beverage | $736.57 |
| Education | $88.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $45,828.84 | 2019-2021 | |
| Abbvie INC. | $24,534.14 | 2020-2025 | |
| Sobi, INC | $7,371.51 | 2022 | |
| Janssen Biotech, INC. | $3,527.80 | 2023-2024 | Darzalex, Talvey, Tecvayli |
| Regeneron Healthcare Solutions, INC. | $1,293.45 | 2022-2024 | Libtayo |
| Amgen INC. | $234.35 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $211.20 | 2020-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $153.70 | 2022-2023 | Imbruvica, Epkinly |
| Intuitive Surgical, INC. | $145.43 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $74.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $47.15 | 2020-2025 | Jemperli |
| Pfizer INC. | $35.23 | 2020 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Blueprint Medicines Corporation | $23.02 | 2020 | |
| Merck Sharp & Dohme LLC | $20.99 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $18.28 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $14.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.66 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Foundation Medicine, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yulian Khagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.